We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · May 28, 2020

Isatuximab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients With Renal Impairment

Leukemia

 

Additional Info

Leukemia
Isatuximab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients With Renal Impairment: ICARIA-MM Subgroup Analysis
Leukemia 2020 May 23;[EPub Ahead of Print], MA Dimopoulos, X Leleu, P Moreau, PG Richardson, AM Liberati, SJ Harrison, H Miles Prince, EM Ocio, S Assadourian, F Campana, L Malinge, D Sémiond, H van de Velde, K Yong

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading